Drug Trial Radar · NCT05970978
A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics
Last checked: Nov 19, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
152
Actual
Start
Aug 28, 2023
Primary completion
Jul 19, 2024
Study completion Jan 26, 2025
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label study aim to evaluate the efficacy and safety of IBI112 in Chinese participants with plaque psoriasis who were treated with biologics and switched to IBI112. The study will enroll 160 participants who were diagnosed with plaque psoriasis. The whole study consists of 4 weeks of screening, 32 or 36 weeks of treatment and a safety follow-up visit at Week 44.
Conditions
- Psoriasis
Interventions
regular treatmentDrug
IBI112 200mg s.c. at week 0, 12, 24 and 36.
Intensive treatmentDrug
IBI112 200mg s.c. at week 0, 4, 8, 20 and 32.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants who achieve sPGA clean (0) or nearly clean (1) ,and BSA < 3%Time frame: Week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dermatology Hospital of Shandong First Medical University (Shandong Provincial Hospitial of Dermatology)
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.